{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:04:29Z","timestamp":1791893069181,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.pharma.2026.09.005","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:28:06Z","timestamp":1790404086000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarqueurs sanguins du traumatisme cr\u00e2nien l\u00e9ger en 2026"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7452-315X","authenticated-orcid":false,"given":"Vincent","family":"Sapin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2026.09.005_bib0320","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/clinchem\/hvae049","article-title":"Blood biomarkers for the management of mild traumatic brain injury in clinical practice","volume":"70","author":"Oris","year":"2024","journal-title":"Clin Chem"},{"key":"10.1016\/j.pharma.2026.09.005_bib0325","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3171\/2017.10.JNS17352","article-title":"Estimating the global incidence of traumatic brain injury","volume":"130","author":"Dewan","year":"2019","journal-title":"J Neurosurg"},{"key":"10.1016\/j.pharma.2026.09.005_bib0330","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/S0140-6736(17)30555-X","article-title":"Accuracy of PECARN, CATCH, and CHALICE head injury decision rules in children: a prospective cohort study","volume":"389","author":"Babl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2026.09.005_bib0335","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1474-4422(25)00154-1","article-title":"A new characterisation of acute traumatic brain injury: the NIH-NINDS TBI Classification and Nomenclature Initiative","volume":"24","author":"Manley","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharma.2026.09.005_bib0340","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1089\/neu.2024.0581","volume":"42","author":"Bazarian","year":"2025","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.pharma.2026.09.005_bib0345","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/0006-291X(65)90320-7","article-title":"A soluble protein characteristic of the nervous system","volume":"19","author":"Moore","year":"1965","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharma.2026.09.005_bib0350","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0361-9230(95)00040-2","article-title":"The S100\u00a0protein family: history, function, and expression","volume":"37","author":"Zimmer","year":"1995","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.pharma.2026.09.005_bib0355","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/jnc.14574","article-title":"The S100B story: from biomarker to active factor in neural injury","volume":"148","author":"Michetti","year":"2019","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharma.2026.09.005_bib0360","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1515\/cclm-2015-0771","article-title":"Preanalytical, analytical, gestational and pediatric aspects of the S100B immunoassays","volume":"54","author":"Bouvier","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0365","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1515\/cclm-2018-1217","article-title":"Measurement of S100B protein: evaluation of a new prototype on a bioM\u00e9rieux Vidas 3\u00a0analyzer","volume":"57","author":"Oris","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0370","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.clinbiochem.2011.05.004","article-title":"Reference ranges for serum S100B protein during the first three years of life","volume":"44","author":"Bouvier","year":"2011","journal-title":"Clin Biochem"},{"key":"10.1016\/j.pharma.2026.09.005_bib0375","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/gerona\/glab055","article-title":"Predictive performance of blood S100B in the management of patients over 65\u00a0years old with mild traumatic brain injury","volume":"76","author":"Oris","year":"2021","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.pharma.2026.09.005_bib0380","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1373\/49.5.836","article-title":"Reference values for serum S-100B protein depend on the race of individuals","volume":"49","author":"Ben Abdesselam","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.pharma.2026.09.005_bib0385","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.injury.2020.03.012","article-title":"Increased S-100B levels are associated with fractures and soft tissue injury in multiple trauma patients","volume":"51","author":"M\u00fcller","year":"2020","journal-title":"Injury"},{"key":"10.1016\/j.pharma.2026.09.005_bib0390","doi-asserted-by":"crossref","first-page":"830","DOI":"10.4085\/1062-6050-49.3.33","article-title":"A systematic review of the biomarker S100B: implications for sport-related concussion management","volume":"49","author":"Schulte","year":"2014","journal-title":"J Athl Train"},{"key":"10.1016\/j.pharma.2026.09.005_bib0395","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/01.shk.0000209534.61058.35","article-title":"Serum S-100B concentration provides additional information for the indication of computed tomography in patients after minor head injury: a prospective multicenter study","volume":"25","author":"Biberthaler","year":"2006","journal-title":"Shock"},{"key":"10.1016\/j.pharma.2026.09.005_bib0400","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/HTR.0b013e3181e57e22","article-title":"Can low serum levels of S100B predict normal CT findings after minor head injury in adults? An evidence-based review and meta-analysis","volume":"25","author":"Und\u00e9n","year":"2010","journal-title":"J Head Trauma Rehabil"},{"key":"10.1016\/j.pharma.2026.09.005_bib0405","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12916-015-0533-y","article-title":"Validation of the Scandinavian guidelines for initial management of minimal, mild and moderate traumatic brain injury in adults","volume":"13","author":"Und\u00e9n","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0410","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1515\/cclm-2018-0471","article-title":"Clinical validation of S100B in the management of a mild traumatic brain injury: issues from an interventional cohort of 1449\u00a0adult patients","volume":"56","author":"Allouchery","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0415","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s12028-024-02189-7","article-title":"Diagnostic accuracy of S100B in predicting intracranial abnormalities on CT imaging following mild traumatic brain injury: a systematic review and meta-analysis","volume":"42","author":"Karamian","year":"2025","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.pharma.2026.09.005_bib0420","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12883-016-0723-z","article-title":"The addition of S100B to guidelines for management of mild head injury is potentially cost saving","volume":"16","author":"Calcagnile","year":"2016","journal-title":"BMC Neurol"},{"key":"10.1016\/j.pharma.2026.09.005_bib0425","first-page":"101260","article-title":"Management of patients suffering from mild traumatic brain injury 2023","volume":"42","author":"Gil-Jardin\u00e9","year":"2023","journal-title":"Anaesth Crit Care Pain Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0430","doi-asserted-by":"crossref","first-page":"e20180037","DOI":"10.1542\/peds.2018-0037","article-title":"The biomarker S100B and mild traumatic brain injury: a meta-analysis","volume":"141","author":"Oris","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharma.2026.09.005_bib0435","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1515\/cclm-2020-1293","article-title":"Impact of routine S100B protein assay on CT scan use in children with mild traumatic brain injury","volume":"59","author":"Lorton","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0440","doi-asserted-by":"crossref","first-page":"5741","DOI":"10.1038\/s41598-025-89927-9","article-title":"Diagnostic performance of S100B assay for intracranial hemorrhage detection in patients with mild traumatic brain injury under antiplatelet or anticoagulant therapy","volume":"15","author":"Poislane","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharma.2026.09.005_bib0445","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.pneurobio.2011.01.005","article-title":"GFAP in health and disease","volume":"93","author":"Middeldorp","year":"2011","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharma.2026.09.005_bib0450","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pharma.2026.09.005_bib0455","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0022-510X(81)90032-0","article-title":"The demonstration of new human brain-specific proteins by high-resolution two-dimensional polyacrylamide gel electrophoresis","volume":"49","author":"Jackson","year":"1981","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pharma.2026.09.005_bib0460","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1042\/BCJ20160082","article-title":"Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunction","volume":"473","author":"Bishop","year":"2016","journal-title":"Biochem J"},{"key":"10.1016\/j.pharma.2026.09.005_bib0465","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1515\/cclm-2026-0471","article-title":"Capillary UCH-L1 protein blood measurement is affected by sample hemolysis","volume":"64","author":"Bouthors","year":"2026","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0470","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.neuchi.2021.01.001","article-title":"Blood biomarkers of mild traumatic brain injury: state of art","volume":"67","author":"Sapin","year":"2021","journal-title":"Neurochirurgie"},{"key":"10.1016\/j.pharma.2026.09.005_bib0475","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1089\/neu.2013.3245","article-title":"GFAP outperforms S100\u03b2 in detecting traumatic intracranial lesions on computed tomography in trauma patients with mild traumatic brain injury and those with extracranial lesions","volume":"31","author":"Papa","year":"2014","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.pharma.2026.09.005_bib0480","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/neu.2015.4149","article-title":"Ability of serum glial fibrillary acidic protein, ubiquitin C-terminal hydrolase-L1, and S100B to differentiate normal and abnormal head computed tomography findings in patients with suspected mild or moderate traumatic brain injury","volume":"33","author":"Welch","year":"2016","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.pharma.2026.09.005_bib0485","doi-asserted-by":"crossref","first-page":"28203","DOI":"10.1038\/srep28203","article-title":"Serum concentrations of ubiquitin C-terminal hydrolase-L1\u00a0and glial fibrillary acidic protein after pediatric traumatic brain injury","volume":"6","author":"Mondello","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharma.2026.09.005_bib0490","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1515\/cclm-2023-0280","article-title":"Serum GFAP\u2013pediatric reference interval in a cohort of Danish children","volume":"61","author":"Tybirk","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0495","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1474-4422(18)30231-X","article-title":"Serum GFAP and UCH-L1\u00a0for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study","volume":"17","author":"Bazarian","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharma.2026.09.005_bib0500","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1089\/neu.2020.7140","article-title":"Point-of-care platform blood biomarker testing of glial fibrillary acidic protein versus S100\u00a0calcium-binding protein B for prediction of traumatic brain injuries: a transforming research and clinical knowledge in traumatic brain injury study","volume":"37","author":"Okonkwo","year":"2020","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.pharma.2026.09.005_bib0505","doi-asserted-by":"crossref","first-page":"105477","DOI":"10.1016\/j.ebiom.2024.105477","volume":"110","author":"Lagares","year":"2024","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.pharma.2026.09.005_bib0510","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.annemergmed.2025.09.012","article-title":"Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase L1 for Acute Traumatic Intracranial Lesions: The PIONEER Diagnostic Accuracy Study","volume":"87","author":"Roberts","year":"2026","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12245-024-00708-z","article-title":"Evaluation of GFAP\/UCH-L1\u00a0biomarkers for computed tomography exclusion in mild traumatic brain injury (mTBI)","volume":"17","author":"Legramante","year":"2024","journal-title":"Int J Emerg Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0520","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.annemergmed.2025.03.018","article-title":"Can the association of the biomarkers GFAP and UCH-L1\u00a0predict intracranial injury after mild traumatic brain injury in adults?. A systematic review and meta-analysis","volume":"87","author":"Puravet","year":"2026","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0525","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.3390\/jcm15134858","article-title":"GFAP and UCH-L1\u00a0for ruling out intracranial lesions after mild traumatic brain injury: a systematic review and meta-analysis","volume":"15","author":"San Miguel","year":"2026","journal-title":"J Clin Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0530","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13049-025-01364-9","article-title":"A head-to-head comparison of S100B and GFAP\/UCH-L1 for detection of traumatic intracranial lesions in a Scandinavian trauma cohort","volume":"33","author":"Wichmann","year":"2025","journal-title":"Scand J Trauma Resusc Emerg Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0535","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1515\/cclm-2024-1034","article-title":"Increased specificity of the \u201cGFAP\/UCH-L1\u201d mTBI rule-out test by age dependent cut-offs","volume":"63","author":"Ladang","year":"2025","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0540","first-page":"47","article-title":"Biomarkers for acute mild brain injury (BAMBI): optimising GFAP\/UCH-L1 thresholds to support CT stewardship in a NICE-guided mild-traumatic-brain-injury cohort","volume":"9","author":"O'Shea","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.pharma.2026.09.005_bib0545","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2352-4642(24)00295-5","article-title":"and UCH-L1\u00a0for the identification of clinically important traumatic brain injury in children in France: a diagnostic accuracy substudy","volume":"9","author":"Puravet","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.pharma.2026.09.005_bib0550","doi-asserted-by":"crossref","first-page":"e083531","DOI":"10.1136\/bmjopen-2023-083531","volume":"14","author":"Lorton","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.pharma.2026.09.005_bib0555","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1515\/cclm-2022-0173","article-title":"Evaluation of serum neurofilament light in the early management of mTBI patients","volume":"60","author":"Kahouadji","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0560","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.neubiorev.2021.11.036","article-title":"Blood-based biomarkers of inflammation in mild traumatic brain injury: a systematic review","volume":"132","author":"Visser","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pharma.2026.09.005_bib0565","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/08977151251385576","article-title":"IL6 in combination with either NfL, NTproBNP, or GFAP to safely discharge children with mild traumatic brain injury","volume":"43","author":"Chiollaz","year":"2026","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.pharma.2026.09.005_bib0570","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrclinonc.2011.76","article-title":"MicroRNAs in body fluids\u2014the mix of hormones and biomarkers","volume":"8","author":"Cortez","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pharma.2026.09.005_bib0575","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jocn.2023.07.011","article-title":"MicroRNA biomarkers for diagnosis of mild traumatic brain injury and prediction of persistent symptoms: a prospective cohort study","volume":"115","author":"Mitra","year":"2023","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.pharma.2026.09.005_bib0580","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3389\/fneur.2020.00528","article-title":"Is salivary S100B a biomarker of traumatic brain injury? A pilot study","volume":"11","author":"Janigro","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.pharma.2026.09.005_bib0585","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/jpm14010035","article-title":"Exploring the potential of exosomal biomarkers in mild traumatic brain injury and post-concussion syndrome: a systematic review","volume":"14","author":"Mavroudis","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0590","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00701-016-3046-3","article-title":"A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury","volume":"159","author":"Thelin","year":"2017","journal-title":"Acta Neurochir"},{"key":"10.1016\/j.pharma.2026.09.005_bib0595","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1474-4422(22)00256-3","article-title":"Prognostic value of day-of-injury plasma GFAP and UCH-L1\u00a0levels for predicting functional recovery in the TRACK-TBI cohort: an observational cohort study","volume":"21","author":"Korley","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharma.2026.09.005_bib0600","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ajem.2025.12.021","article-title":"Prognostic value of GFAP and UCHL-1\u00a0biomarkers in high-risk mild traumatic brain injury: a prospective longitudinal study of short- and long-term outcomes","volume":"101","author":"Spaziani","year":"2026","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.pharma.2026.09.005_bib0605","doi-asserted-by":"crossref","first-page":"36791","DOI":"10.1038\/srep36791","article-title":"Serum neurofilament light protein predicts clinical outcome in traumatic brain injury","volume":"6","author":"Shahim","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharma.2026.09.005_bib0610","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/neu.2022.0148","article-title":"Blood biomarkers for return to play after concussion in professional rugby players","volume":"40","author":"Oris","year":"2023","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.pharma.2026.09.005_bib0615","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/bjsports-2017-097699","article-title":"Consensus statement on concussion in sport\u2014the 5th international conference on concussion in sport held in Berlin, October 2016","volume":"51","author":"McCrory","year":"2017","journal-title":"Br J Sports Med"},{"issue":"1","key":"10.1016\/j.pharma.2026.09.005_bib0620","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s40798-026-01094-x","article-title":"Evaluation of GFAP, UCH-L1\u00a0and S100B blood biomarkers for the management of sports-related concussion in professional rugby players: a prospective observational study","volume":"12","author":"Oris","year":"2026","journal-title":"Sports Med Open"},{"key":"10.1016\/j.pharma.2026.09.005_bib0625","doi-asserted-by":"crossref","first-page":"101686","DOI":"10.1016\/j.neuchi.2025.101686","article-title":"Mild traumatic brain injury: an update. Report of the French Society of Neurosurgery and the French-Speaking Neurosurgical Society","volume":"71","author":"Manet","year":"2025","journal-title":"Neurochirurgie"},{"key":"10.1016\/j.pharma.2026.09.005_bib0315","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12245-026-01292-0","article-title":"Consensus statements for the diagnosis of mild traumatic brain injury and clinical integration of blood-based biomarkers in the Asia-Pacific region: a modified Delphi study","volume":"19","author":"Kuan","year":"2026","journal-title":"Int J Emerg Med"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926001446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926001446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:29:49Z","timestamp":1791890989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450926001446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":63,"alternative-id":["S0003450926001446"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2026.09.005","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarqueurs sanguins du traumatisme cr\u00e2nien l\u00e9ger en 2026","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2026.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}